Immune Efficacy of a Genetically Engineered Vaccine against Lymphocystis Disease Virus: Analysis of Different Immunization Strategies

Figure 4

Detection of LCDV-specific antibodies from the sera of DNA-vaccinated Japanese flounder collected on days 21, 35, 56, and 90 after vaccination by ELISA. (a) Intramuscular injection; (b) hypodermic injection. 15 μg pEGFP-N2-LCDV-cn0.6 kb group (plus sign); 5 μg pEGFP-N2-LCDV-cn0.6 kb group (asterisk); 0.1 μg pEGFP-N2-LCDV-cn0.6 kb group (horizontal line); pEGFP-N2 group (triangle); PBS group (square); no injection (block dot). Results are shown as the mean ± S.E.M. of the OD₄₅₀ values.

(a)

(b)